Skip to main content
Log in

The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function

  • Original Article
  • Cisplatin, Ageing, Pharmacokinetics
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

This study was performed to identify any relationship between age and cisplatin (CDDP) pharmacokinetics in lung cancer patients. CDDP was given at a dose of 80 mg/m2 by 1-h intravenous infusion to 23 lung cancer patients. All patients had normal renal, hepatic, and bone marrow functions. We measured ultrafilterable platinum (U-Pt) and total plasma platinum (T-Pt) using atomic absorption spectrometry. There was significant correlation between the age of the patients and U-Pt pharmacokinetic parameters such as the area under the plasma concentration versus time curve (AUC), total clearance (Cl), and peak plasma concentration (Cmax) as well as the AUC of T-Pt (P<0.05). We performed univariate regression analysis to examine the influence of factors aside from age on the AUC of U-Pt and T-Pt. Creatinine and GPT levels were significantly related to the AUC of U-Pt, and creatinine clearance and creatinine concentrations were significantly related to the AUC of T-Pt. Therefore, stepwise multiple-regression models for the AUC of U-Pt and T-Pt were developed to assess an age effect. Age was consistently an independent and significant predictor of the AUC of U-Pt and T-Pt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Borkowski JM, Duerr M, Donehower RC, Rowinsky EK, Chen TL, Ettinger DS, Grochow LB (1994) Relation between age and the clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 33:493

    Google Scholar 

  2. Bunn PA (1989) The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16:10

    Google Scholar 

  3. Greenblatt DJ, Koch-Water J (1975) Drug therapy: clinical pharmacokinetics. N Engl J Med 293:702

    Google Scholar 

  4. Miya T, Sasaki Y, Karato A, Saijo N (1992) Pharmacokinetic study of mitomycin C with emphasis on the influence of ageing. Jpn J Cancer Res 83:1382

    Google Scholar 

  5. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFradden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649

    Google Scholar 

  6. Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14:177

    Google Scholar 

  7. Reece PA, Stafford I, Russel J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafiltreable platinum plasma levels and nephrotoxicity. J Clin Oncol 5:304

    Google Scholar 

  8. Schmucker DL (1985) Ageing and drug disposition: an update. Pharmacol Rev 37:133–148

    Google Scholar 

  9. Tregaskins BF, Stevenson IH (1990) Pharmacokinetics in old age. Br Med Bull 46:9

    Google Scholar 

  10. Weiner MW, Jacobs C (1983) Mechanism of cisplatin nephrotoxicity. Fed Proc 42:2974

    Google Scholar 

  11. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165

    Google Scholar 

  12. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputers. J Pharmacobiodyn 4:879

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, N., Tamura, T., Maeda, M. et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother. Pharmacol. 36, 102–106 (1995). https://doi.org/10.1007/BF00689192

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689192

Key words

Navigation